Thian Chew

Thian Chew is Chairman & CEO of Invion Limited (ASX:IVX), a clinical stage life sciences firm leading the development of PhotosoftTM, a next generation photodynamic therapy (PDT) used for treating a range of cancers and infectious diseases. He is also Co-Founder of Chronic Airway Therapeutics, which is undertaking clinical trials for treatment of respiratory diseases. 

He is Managing Partner at Polar Ventures, and was Executive Director at Goldman Sachs (New York, Hong Kong) responsible for the firm’s proprietary investments.  Prior to this, Thian worked at Morgan Stanley’s Strategic Services Group (New York) and spent a decade at KPMG (Melbourne, Taipei, Sydney, Singapore) taking multiple roles across Asia Pacific, including leading business transformation and post-merger integration programs.

Thian holds an MBA from the Wharton School (Palmer Scholar) / MA (Lauder Institute), University of Pennsylvania, and a B. Information Systems from Monash University.  He is also an Adjunct Professor at the Hong Kong University of Science & Technology (Business, Life Sciences).